KRAS and lung carcinoma: Importantly, regardless of whether there is an exclusive association between KRAS mutation and TWIST1 overexpression in human lung cancer cells, the data presented strongly support that TWIST1 upregulation in KRAS mutant lung cancer represents a novel and particularly promising therapeutic target.